Xencor (XNCR) Accumulated Expenses (2013 - 2026)
Xencor (XNCR) reported Accumulated Expenses of $34.3 million for Q1 2026, up 113.24% year-over-year from $16.1 million in Q1 2025, and down 2.02% quarter-over-quarter from $35.0 million in Q4 2025.
Xencor (XNCR) Accumulated Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Accumulated Expenses data on file, last reported at $34.3 million in Q1 2026.
- Accumulated Expenses for Q1 2026 came in at $34.3 million, up 113.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.3 million (up 113.24% YoY), and the FY2025 annual result was $35.0 million, up 81.92% from the prior year.
- Accumulated Expenses eased to $34.3 million in Q1 2026 per XNCR's latest filing, from $35.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $35.0 million in Q4 2025 and troughed at $12.6 million in Q1 2022.
- A 5-year average of $21.4 million and a median of $19.3 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses dropped 18.45% in 2024, then jumped 113.24% in 2026.
- A 5-year view of Accumulated Expenses shows it stood at $18.7 million in 2022, then gained by 25.82% to $23.6 million in 2023, then declined by 18.45% to $19.2 million in 2024, then soared by 81.92% to $35.0 million in 2025, then dropped by 2.02% to $34.3 million in 2026.
- Business Quant data shows XNCR's Accumulated Expenses at $34.3 million in Q1 2026, $35.0 million in Q4 2025, and $28.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.25 Mn |
| Dec 31, 2025 | 34.96 Mn |
| Sep 30, 2025 | 28.11 Mn |
| Jun 30, 2025 | 23.88 Mn |
| Mar 31, 2025 | 16.06 Mn |
| Dec 31, 2024 | 19.22 Mn |
| Sep 30, 2024 | 25.41 Mn |
| Jun 30, 2024 | 19.56 Mn |
| Mar 31, 2024 | 13.49 Mn |
| Dec 31, 2023 | 23.56 Mn |
| Sep 30, 2023 | 24.47 Mn |
| Jun 30, 2023 | 18.44 Mn |
| Mar 31, 2023 | 15.14 Mn |
| Dec 31, 2022 | 18.73 Mn |
| Sep 30, 2022 | 19.29 Mn |
| Jun 30, 2022 | 16.35 Mn |
| Mar 31, 2022 | 12.61 Mn |
| Dec 31, 2021 | 19.44 Mn |
| Sep 30, 2021 | 22.11 Mn |
| Jun 30, 2021 | 17.33 Mn |